First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort 2 of the 64Cu/67Cu SARTATE™ neuroblastoma...
Read more: First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial